Toric IOLs good choice to correct astigmatism

Article

Residual astigmatism plays an important role in the quality of visual outcome after cataract surgery, so astigmatism correction must be targeted during cataract surgery. This is especially relevant in cases over 3 D of corneal astigmatism.

Residual astigmatism plays an important role in the quality of visual outcome after cataract surgery, so astigmatism correction must be targeted during cataract surgery. This is especially relevant in cases over 3 D of corneal astigmatism, said Jorge Alio, MD at the Acri.Tec symposium.

"Cataract surgery should not induce or change pre-existing astigmatism. It needs to be controlled, stable and precise and correction should not induce other optical changes, such as increased aberrations as this will cause a shift in the spherical correction of the eye," said Dr Alio.

Toric IOLs are a good choice because they offer full correction of the whole refractive error, and may correct for an unlimited amount of astigmatism.

Dr Alio outlined one cataract patient with preoperative UCVA counting fingers at 2 metres, with refraction of -4.5 sphere -6.5 and cylinder of 10. The patient underwent microincision cataract surgery (MICS) with Acri.Tec's Acri.Comfort 646 TLC implantation. The power was refraction +15.5, sphere +6.5 and cylinder of 100, achieving postoperative goal refraction of -0.27 sphere and -0.11 cylinder.

"Immediately, in the first postoperative day, the patient achieved 0.2 UCVA," said Dr Alio. "At three months postoperatively the patient had a UCVA 0.4, BCVA 0.5 with a refraction of 1, sphere -1 and cylinder 130," enthused Dr Alio.

The Acri.Comfort 646 is the only commercially available Toric MICS IOL, and it offers an unlimited amount of astigmatic correction during cataract surgery, according to Dr Alio. "Its rotational stability is excellent, and it gives outstanding refractive outcomes. It is the Toric pseudophakic IOL of choice in our clinic," he concluded.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.